Grant From NMSS

October 27, 2017
Longevity Biotech Awarded Grant From National Multiple Sclerosis Society to Evaluate LBT-3627 as a Novel Drug Candidate for Multiple Sclerosis

​​​​​Longevity Biotech, Inc. (LBT) has received an award from the National Multiple Sclerosis Society through Fast Forward, the Society’s commercial research funding program, to evaluate LBT-3627 in preclinical models as a potential disease-modifying therapeutic agent.

Continue to news room.

Continue to press release.